Does good old Velcade add anything to anti-CD38+Rd in older adults with #Myeloma ?

BENEFIT (IFM) study #ASCO24 shows it does, but with tradeoffs! MRD-neg 10^-6 @ 18 mo. (ITT) ~2x greater w Isa-VRd vs Isa-Rd!

No diff. in PFS/OS yet.

G>=2 neuropathy ⬆️by ~1.5 fold!
#mmsm

📢🎺 Dear rheumatologists, your patients with autoimmune diseases do NOT need to be tested for MGUS !!

No association between autoimmune disease and MGUS according to this study by the iStopMM.

acpjournals.org/doi/10.7326/M2…

HD melphalan + autoHCT in AL amyloidosis following dara-based frontline Rx, N=13, 100-day TRM: 0, 63% MRD -ve at 100 day, 1005 cardiac response. 3-year EFS: 89% Raj Chakraborty Suzanne Lentzsch, MD, PhD Markus Y. Mapara 🇺🇦 #mmsm #bmtsm nature.com/articles/s4140…

Raj Chakraborty Manni Mohyuddin CancerWarrior51 International Myeloma Foundation Agree seli is neither groundbreaking nor remarkable. Marginal with significant side effects rather…
Very very limited use in clinical practice. …

Excited to have the first BCMA Bispecific Antibody trial in relapsed/refractory AL #Amyloidosis now open for accrual at Herbert Irving Comprehensive Cancer Center CAMP@CUIMC! Patient-friendly Q-4 weekly schedule from the get-go.
Suzanne Lentzsch, MD, PhD Amyloidosis Support

Timing and Outcomes of 2nd line therapy in the era of frontline Dara-VCd in AL #Amyloidosis -Our experience CAMP@CUIMC to be presented at #EHA24 by Abdul-Hamid Bazarbachi, MD!
Suzanne Lentzsch, MD, PhD
tinyurl.com/mrkvaxjf

Also Online First:

#Overallsurvival benefits of #cancerdrugs initially approved by the US Food and Drug Administration U.S. FDA on the basis of immature survival data: a retrospective analysis
thelancet.com/journals/lanon…

Wanting stronger control arms & meaningful surrogate endpoints, initiating studies about deescalation & sequencing, and investigating careful observation vs early tx &/or forever mx -- these are all a vital part of, not pursuits in opposition to, 'patient choice.' 1/3

A thoughtful thread on how to think about ASCT in the era of quads! As Luciano J Costa eloquently implies, it all comes down to risk/benefit!

Fit 76 y/o with Double-Hit myeloma: I will try to convince my pt. to do ASCT!

Fit 74 y/o standard-risk with good post-induction response:

My coMMit colleagues are answering this question on a randomized trial. Binod Dhakal Natalie Callander Timothy Schmidt, MD Larry Anderson,MD,PhD,FACP Henning Schade Raj Chakraborty. 9/X

Discussing smoldering. Aaron Goodman - “Papa Heme”

Darren Dahly - on Bluesky and Substack I shudder whenever I read “clinical trial emulation”. How do you emulate blinding or guarantee that all confounders are measured? How do you start the clock at the same time for every patient?

If you have myeloma or its precursor conditions, we would love for you to do a quick survey on preferences in situations where survival may be similar between different approaches.

If you registered on HealthTree Foundation this link should take you to survey:

qrco.de/myelomasurveyp…

Beautiful example of how a study demonstrating a statistical association is quickly turned into one making a causal claim.

🔥 Tune in to our new episode on maintenance therapy in #MultipleMyeloma with Hira Mian & Manni Mohyuddin ! We discuss a wide range of RCTs from CALGB to FORTE, ideal endpoints for maintenance trials, and role of MRD!
tinyurl.com/4mtjyz6m
Here is clip on Dara maint. in CASSIOPEIA!

👍🏽editorial by Angela Dispenzieri on FLC-Mass Spect in AL amyloidosis by awechalekar's group. I love the way Dr. Dispenzieri masterfully distills the key findings in one figure! A must-read and should be a benchmark for how to write an excellent commentary.
tinyurl.com/yjchc87z

Manni Mohyuddin Aaron Goodman - “Papa Heme” Comm onc here. COI: I'm a vegetarian. I tell my pts to eat/drink in moderation. For some, being able to do that is QoL. Grandma advice is good for now. Everything else is acad hubris unless some study shows otherwise. Vegan diets also cause time and financial tox in the community

Myeloma needs more therapy de-escalation trials. Won’t happen as long as pharma is running the show but we need to demand it. Do we really need duplicate single arm studies treating healthy people (smoldering myeloma)?

Important paper showing overall positive trend with 42% of first authors = female in 2019 (although wide range between countries).

Agree that WHY is the big question, so need to know what is the proportion of M vs. F oncologists in each country? How many are doing research and